Cargando…

Importance of ROS1 gene fusions in non-small cell lung cancer

Targeted therapy has become one of the standards of care for advanced lung cancer. More than 10 genetic aberrations have been discovered that are actionable and several tyrosine kinase inhibitors (TKIs) have been approved to target each of them. Among several genetic aberrations that are actionable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muminovic, Meri, Carracedo Uribe, Carlos Rodrigo, Alvarez-Pinzon, Andres, Shan, Khine, Raez, Luis E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344718/ https://www.ncbi.nlm.nih.gov/pubmed/37457125 http://dx.doi.org/10.20517/cdr.2022.105

Ejemplares similares

Mortality and prognostic factors in hospitalized COVID-19 patients with cancer: an analysis from a large healthcare system in the United States
por: Raez, Luis E., et al.
Publicado: (2022)

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
por: Gendarme, Sébastien, et al.
Publicado: (2022)

Therapeutic vaccines in non-small cell lung cancer
por: Socola, Francisco, et al.
Publicado: (2013)

Prevalence of ROS1 fusion in Chinese patients with non‐small cell lung cancer
por: Zhang, Qing, et al.
Publicado: (2018)

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
por: Lin, Jessica J., et al.
Publicado: (2020)

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
por: Wu, Chi‐Hao, et al.
Publicado: (2021)

Clinical characteristics of non‐small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions
por: Liu, Qinghua, et al.
Publicado: (2022)

Novel SLC12A2‐ROS1 Fusion in Non‐Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next‐Generation Sequencing Assay
por: Rodríguez‐Antolín, Carlos, et al.
Publicado: (2021)

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing
por: Nagasaka, Misako, et al.
Publicado: (2023)

Microvesicles: ROS scavengers and ROS producers
por: Bodega, G., et al.
Publicado: (2019)

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
por: Cai, Liangliang, et al.
Publicado: (2020)

Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
por: Soberanis Pina, Pamela, et al.
Publicado: (2023)

Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion
por: Shu, Yun, et al.
Publicado: (2023)

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
por: Corrales, Luis, et al.
Publicado: (2017)

ROS1 copy number alterations are frequent in non-small cell lung cancer
por: Clavé, Sergi, et al.
Publicado: (2016)

ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer
por: Liu, Zheng, et al.
Publicado: (2020)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
por: Dziadziuszko, Rafal, et al.
Publicado: (2021)

Exosomal microRNAs in non-small cell lung cancer
por: Duréndez-Sáez, Elena, et al.
Publicado: (2021)

High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer
por: Zhang, Limin, et al.
Publicado: (2019)

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants
por: Xu, Haiyan, et al.
Publicado: (2020)

Clinic-pathologic features and gene fusion pattern of ALK and ROS1 in non-small cell lung cancer show association with household coal combustion
por: Chen, Ying, et al.
Publicado: (2019)

Detecting ALK , ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA‐based techniques
por: Giménez‐Capitán, Ana, et al.
Publicado: (2023)

Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021)

Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma
por: Ribeiro, Maurício Fernando Silva Almeida, et al.
Publicado: (2022)

Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy
por: Raez, Luis E., et al.
Publicado: (2020)

ROS1 Immunohistochemistry Among Major Genotypes of Non—Small-Cell Lung Cancer
por: Boyle, Theresa A., et al.
Publicado: (2014)

Testing for ROS1 in non-small cell lung cancer: a review with recommendations
por: Bubendorf, Lukas, et al.
Publicado: (2016)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
por: Stanzione, Brigida, et al.
Publicado: (2023)

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients
por: Castellanos-Rizaldos, Elena, et al.
Publicado: (2019)

Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement
por: Wu, Jieyu, et al.
Publicado: (2016)

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study
por: Fujiwara, Yutaka, et al.
Publicado: (2018)

Effective Treatment with Cabozantinib in an Advanced Non-Small-Cell Lung Cancer Patient Harboring a CD74-ROS1 Fusion: A Case Report
por: Wang, Gang, et al.
Publicado: (2020)

Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms
por: Mayer, Chen, et al.
Publicado: (2022)

Erlotinib induces the human non–small‐cell lung cancer cells apoptosis via activating ROS‐dependent JNK pathways
por: Shan, Fenglian, et al.
Publicado: (2016)

Non-small-cell lung cancer classification via RNA-Seq and histology imaging probability fusion
por: Carrillo-Perez, Francisco, et al.
Publicado: (2021)

ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes
por: Joshi, Amit, et al.
Publicado: (2019)

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
por: Rossi, Giulio, et al.
Publicado: (2017)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2017)

Guaiazulene Triggers ROS-Induced Apoptosis and Protective Autophagy in Non-small Cell Lung Cancer
por: Ye, Qin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2soqudjhk2areqta0ueqe18pin